Fannin
Atul Varadhachary is a distinguished leader in the life sciences sector, currently serving as the Chief Executive Officer of Radiomer Therapeutics since January 2024, focusing on innovative targeted radiopharmaceuticals. Varadhachary has been the Managing Partner at Fannin since June 2013, overseeing numerous biotech and medtech programs. Additionally, Varadhachary has held the role of Chief Executive Officer at Allterum Therapeutics since July 2018, where the company is developing a first-in-class cancer treatment. Varadhachary is actively involved in several organizations, including serving on the Advisory Committee on Childhood Cancers for the Cancer Prevention and Research Institute of Texas and contributing as a board member for both BioHouston and Pulmotect, Inc. Prominent involvement in entrepreneurship is highlighted through leadership roles in TiE and an adjunct professorship at Rice University, where Varadhachary has educated future leaders in entrepreneurship and biotechnology. Varadhachary holds a Ph.D. in Physiology from The Johns Hopkins University School of Medicine and an M.D. from the University of Mumbai.
This person is not in any teams
Fannin
Fannin is an early-stage life sciences development group focused on commercializing innovation developed in the Texas Medical Center institutions. Led by an experienced team of managers with diverse business backgrounds, commercialization experience, and strong entrepreneurial knowhow, Fannin partners with promising life science innovators to co-found and actively manage startup companies. Fannin provides its startups with central office space, seed capital and a vast network of resources. To address the root cause of Houston’s commercialization gap, Fannin works directly with the city’s top-tier, higher education institutions to recruit aspiring entrepreneurs to join its apprenticeship program which provides on-the-job training to collaboratively lead its portfolio companies from innovation to commercialization. Future Outlook: Fannin has successfully validated this business model over the last seven years and is now in the process of scaling it up. Another 15-20 portfolio companies are expected to be developed in the next 3 - 5 years. For more information, email innovate@fannininnovation.com.